Longboard pharmaceuticals to host call to discuss topline data from the pacific study, a phase 1b/2a clinical trial for bexicaserin (lp352) in participants with developmental and epileptic encephalopathies (dees)

La jolla, calif.--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host a conference call to discuss topline data from the pacific study, a phase 1b/2a clinical trial evaluating bexicaserin (lp352) in participants with a broad range of developmental and epileptic encephalopathies (dees). bexicaserin is a potentially best-in-clas.
LBPH Ratings Summary
LBPH Quant Ranking